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Heat-labile enterotoxin B subunit (LTB) of enterotoxigenic Escherichia coli (ETEC) is both a strong
mucosal adjuvant and immunogen. It is a subunit vaccine candidate to be used against ETEC-induced
diarrhea. It has already been expressed in several bacterial and plant systems. In order to construct
yeast expressing vector for the LTB protein, the eltB gene encoding LTB was amplified from a human
origin enterotoxigenic E. coli DNA by PCR. The expression plasmid pLTB83 was constructed by insert-
ing the eltB gene into the pYES2 shuttle vector immediately downstream of the GAL1 promoter. The
recombinant vector was transformed into S. cerevisiae and was then induced by galactose. The LTB
protein was detected in the total soluble protein of the yeast by SDS-PAGE analysis. Quantitative
ELISA showed that the maximum amount of LTB protein expressed in the yeast was approximately
1.9% of the total soluble protein. Immunoblotting analysis showed the yeast-derived LTB protein was
antigenically indistinguishable from bacterial LTB protein. Since the whole-recombinant yeast has
been introduced as a new vaccine formulation the expression of LTB in S. cerevisiae can offer an inex-
pensive yet effective strategy to protect against ETEC, especially in developing countries where it is
needed most.
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ETEC is the most common cause of diarrhea, especially
in young children, travelers and military personnel in
developing countries (Katz et al., 2003; Steinsland et al.,
2003). The major disease agent of ETEC is the heat-labile
enterotoxin (LT). The LT is a plasmid-encoded, high-
molecular weight toxin, which is immunologically and
physicochemically related to cholera toxin (CT) (Guidry
et al., 1997; Fleckenstein et al., 2000).
The crystal structure of LT revealed that it is composed
of one A subunit (LTA) (27 kDa) and five non-covalently
associated B subunits (LTB) (11.6 kDa each) forming a
ring-like pentamer. LTA has ADP-ribosilating activity that
causes constitutive activation of adenylate cyclase, an
increase in the intracellular cAMP and subsequent severe
diarrhea (Nataro and Kaper, 1998; Kozuka et al., 2000).
LTB is able to bind to ganglioside GM1 [Gal(β1-3)Gal-
NAc(β1-4)(NeuAc(α2-3))Gal(β1-4)Glc(β1-1)ceramide],
a glycosphingolipid found ubiquitously on the cell mem-
branes of mammals and to other related receptors, such as
GD1b-ganglioside, asialo-GM1, lactosylceramide and
certain galactoproteins (Williams et al., 1999). The LT
and its related cholera toxin (CT) are extremely potent
immunogens following mucosal or systemic delivery.
It has been shown that LT acts as a strong mucosal adju-
vant, which enhances serum and local immune responses
to co-administered antigens, where most antigens are
unable to induce immune responses. Therefore, it is not
surprising that LT has been incorporated into putative
mucosal vaccines to guard against a range of infectious
agents. However, its inherent toxicity and allergenicity
have hampered progress for human use (Williams et al.,
1999).
One approach to overcome these problems is the use of
a non-toxic derivative of LT, like LTB in isolation. Several
studies with animal models and one human trial demon-
strated that recombinant LTB (rLTB) can stimulate strong
serum and mucosal immune responses against LT. Many
studies have indicated that LTB could be used as a potent
adjuvant (Tochikubo and Yasuda, 2000). Other investiga-
tions have also suggested that the rLTB can increase tol-
erance to heterologous antigens, a finding that has led to
its further application in attempts to prevent autoimmune
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